President Donald Trump signed an executive order on Monday overhauling federal childhood vaccine recommendations, narrowing the list of universally recommended vaccines to 11. The directive aims to align U.S. practices with other developed nations and calls for the potential separation of combined vaccines, specifically the measles, mumps, and rubella (MMR) shot. This policy shift creates immediate uncertainty for major pharmaceutical manufacturers, including Merck & Co Inc., GSK PLC, and Sanofi SA, whose combined vaccine products may face reduced demand or regulatory hurdles.

The order categorizes childhood vaccines into three groups: those recommended for all children, those for high-risk groups, and those requiring shared clinical decision-making. The 11 core vaccines identified are measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Hib, pneumococcal disease, HPV, and varicella. Trump stated at the White House signing ceremony that only these 11 vaccinations meet the "gold standard," adding that the MMR vaccine should be offered as three separate shots once single-disease products are available domestically.

Regulatory Timeline and Corporate Impact

The Department of Health and Human Services (HHS) has been directed to develop plans within 90 days for single-vaccine options, alternative adjuvants, and stronger safety monitoring. States have also been advised to review school vaccination requirements and exemptions. This regulatory pressure directly impacts key products from major healthcare firms:

These vaccines protect against measles, mumps, rubella, varicella, and other childhood diseases. The companies did not immediately respond to requests for comment regarding the financial or operational implications of the order.

Political and Medical Backlash

The executive order faced immediate criticism from medical professionals and politicians. Senator Bill Cassidy (R-La.), a physician, called the order "wrong" on X, stating that vaccines are "overwhelmingly safe" and do not cause autism. He urged parents to follow pediatrician advice rather than the executive order, arguing that breaking up vaccines would require children to receive more shots for the same protection.

Trump repeatedly cited rising autism diagnoses during the signing ceremony, suggesting a link between vaccines and autism rates in certain demographics. This follows previous claims by Trump linking Kenvue Inc.’s Tylenol use during pregnancy to autism, which medical groups disputed. HHS Secretary Robert F. Kennedy Jr., who has promoted disputed claims about vaccines and autism, stated last week that the administration had identified interventions "almost certainly causing autism." The divergence between the administration’s stance and mainstream medical consensus highlights significant regulatory and reputational risks for the pharmaceutical sector.

President Trump has demanded compensation from Iran, stating that representatives of the Islamic Republic sought damages for losses incurred during a five-month military conflict. Trump described the Iranian request as an "interesting idea" and declared that he is "likewise demanding compensation" from Iran — a claim he said had never been raised in any prior negotiations or diplomatic meetings.

Official Statement

The announcement was made via a post on Truth Social. Trump highlighted that while Iranian representatives asked for compensation for damage done to them during the last five months of military conflict, the topic had been entirely absent from all previous diplomatic discussions. He instructed his own representatives to actively pursue a reciprocal compensation claim against Iran.

Key Details

The statement marks a notable shift in diplomatic posture, moving from a position where such financial claims were absent from discussions to one where reciprocal compensation is being actively pursued by the United States.